A Phase Ii Trial of Brentuximab Vedotin (Bv) and Lenalidomide (Len) in Relapsed and Refractory (R/R) Cutaneous (Ctcl) and Peripheral (Ptcl) T-Cell Lymphomas: Preliminary Results of a Phase Ii Trial
Hematological Oncology - United Kingdom
doi 10.1002/hon.150_2631
Full Text
Open PDFAbstract
Available in full text
Date
June 1, 2019
Authors
Publisher
Wiley